Atossa Therapeutics (NASDAQ:ATOS) Earns Buy Rating from HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $7.00 target price on the stock.

Separately, Ascendiant Capital Markets raised their price objective on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a report on Monday, December 9th.

Atossa Therapeutics Trading Up 0.3 %

NASDAQ ATOS opened at $0.70 on Wednesday. The company has a market capitalization of $87.88 million, a PE ratio of -3.18 and a beta of 1.20. Atossa Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.31. The firm’s fifty day simple moving average is $0.79 and its 200-day simple moving average is $1.11.

Atossa Therapeutics (NASDAQ:ATOS) last posted its earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. As a group, analysts predict that Atossa Therapeutics will post -0.22 EPS for the current year.

Hedge Funds Weigh In On Atossa Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Intech Investment Management LLC acquired a new stake in shares of Atossa Therapeutics in the 3rd quarter valued at approximately $29,000. The Manufacturers Life Insurance Company acquired a new position in Atossa Therapeutics in the 3rd quarter valued at $75,000. State Street Corp raised its position in shares of Atossa Therapeutics by 4.2% in the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock valued at $2,633,000 after buying an additional 69,180 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Atossa Therapeutics by 101.2% during the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock worth $75,000 after purchasing an additional 24,951 shares in the last quarter. Finally, Barclays PLC grew its stake in Atossa Therapeutics by 280.9% during the third quarter. Barclays PLC now owns 167,718 shares of the company’s stock worth $255,000 after buying an additional 123,683 shares in the last quarter. 12.74% of the stock is owned by institutional investors and hedge funds.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.